| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 15 | 2024 | 139 | 5.250 |
Why?
|
| Myelodysplastic Syndromes | 28 | 2025 | 368 | 5.130 |
Why?
|
| Leukemia, Myeloid, Acute | 40 | 2025 | 815 | 5.080 |
Why?
|
| Primary Myelofibrosis | 16 | 2024 | 67 | 3.540 |
Why?
|
| Azacitidine | 14 | 2025 | 148 | 2.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 32 | 2025 | 2556 | 1.910 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 22 | 2024 | 923 | 1.880 |
Why?
|
| Antineoplastic Agents | 22 | 2023 | 2368 | 1.640 |
Why?
|
| Sulfonamides | 8 | 2025 | 328 | 1.540 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 5 | 2025 | 22 | 1.480 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2023 | 598 | 1.400 |
Why?
|
| Hematologic Neoplasms | 12 | 2022 | 355 | 1.320 |
Why?
|
| Transplantation Conditioning | 18 | 2020 | 380 | 1.300 |
Why?
|
| Blast Crisis | 5 | 2024 | 37 | 1.280 |
Why?
|
| Stem Cell Transplantation | 5 | 2018 | 190 | 1.250 |
Why?
|
| Pyrimidines | 12 | 2023 | 378 | 1.090 |
Why?
|
| Benzamides | 7 | 2020 | 239 | 1.020 |
Why?
|
| Mitoxantrone | 5 | 2020 | 68 | 1.010 |
Why?
|
| Mutation | 20 | 2024 | 4204 | 1.010 |
Why?
|
| Humans | 127 | 2025 | 92337 | 0.940 |
Why?
|
| Aged | 64 | 2025 | 19943 | 0.890 |
Why?
|
| Treatment Outcome | 40 | 2025 | 8740 | 0.880 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2021 | 57 | 0.880 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2023 | 106 | 0.870 |
Why?
|
| Bridged-Ring Compounds | 2 | 2020 | 14 | 0.840 |
Why?
|
| Aminopyridines | 2 | 2021 | 45 | 0.830 |
Why?
|
| Triazines | 2 | 2021 | 55 | 0.830 |
Why?
|
| Aged, 80 and over | 32 | 2025 | 6916 | 0.810 |
Why?
|
| Transplantation, Homologous | 19 | 2020 | 1015 | 0.790 |
Why?
|
| Middle Aged | 63 | 2025 | 27030 | 0.780 |
Why?
|
| Cytarabine | 9 | 2023 | 222 | 0.780 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2024 | 24 | 0.750 |
Why?
|
| Janus Kinase 2 | 7 | 2021 | 59 | 0.740 |
Why?
|
| Male | 71 | 2025 | 43925 | 0.700 |
Why?
|
| Pyrrolidines | 1 | 2020 | 60 | 0.680 |
Why?
|
| Enzyme Inhibitors | 3 | 2021 | 652 | 0.660 |
Why?
|
| Depsipeptides | 2 | 2010 | 29 | 0.650 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2010 | 112 | 0.630 |
Why?
|
| Leukemia | 6 | 2022 | 321 | 0.610 |
Why?
|
| Female | 69 | 2025 | 47893 | 0.610 |
Why?
|
| Disease Management | 5 | 2020 | 340 | 0.580 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 7 | 2023 | 130 | 0.580 |
Why?
|
| DNA Modification Methylases | 1 | 2017 | 29 | 0.570 |
Why?
|
| Benzimidazoles | 2 | 2019 | 109 | 0.550 |
Why?
|
| Adult | 48 | 2025 | 27532 | 0.540 |
Why?
|
| Neoplasms | 9 | 2023 | 3117 | 0.540 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2025 | 97 | 0.540 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2015 | 98 | 0.530 |
Why?
|
| Clinical Trials as Topic | 5 | 2025 | 1150 | 0.520 |
Why?
|
| Pyrazoles | 5 | 2020 | 153 | 0.510 |
Why?
|
| Hydroxamic Acids | 2 | 2017 | 50 | 0.490 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2012 | 174 | 0.490 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2024 | 236 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 291 | 0.460 |
Why?
|
| Disease Progression | 8 | 2020 | 1503 | 0.440 |
Why?
|
| Precision Medicine | 4 | 2021 | 425 | 0.440 |
Why?
|
| Uridine | 4 | 2025 | 58 | 0.440 |
Why?
|
| Medical Oncology | 4 | 2025 | 393 | 0.420 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2016 | 91 | 0.410 |
Why?
|
| Eosinophilia | 2 | 2014 | 86 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 462 | 0.410 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2012 | 4 | 0.410 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 12 | 0.410 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 16 | 0.410 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2012 | 18 | 0.400 |
Why?
|
| Remission Induction | 11 | 2025 | 763 | 0.400 |
Why?
|
| Core Binding Factors | 2 | 2011 | 12 | 0.400 |
Why?
|
| Thrombocytopenia | 6 | 2023 | 183 | 0.400 |
Why?
|
| Cough | 1 | 2012 | 56 | 0.400 |
Why?
|
| Epigenomics | 2 | 2023 | 103 | 0.390 |
Why?
|
| Dyspnea | 1 | 2012 | 80 | 0.390 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 176 | 0.380 |
Why?
|
| Prognosis | 13 | 2025 | 3872 | 0.370 |
Why?
|
| Mutation, Missense | 1 | 2013 | 288 | 0.360 |
Why?
|
| Genes, ras | 3 | 2019 | 97 | 0.350 |
Why?
|
| Genomics | 4 | 2022 | 806 | 0.340 |
Why?
|
| Graft vs Host Disease | 8 | 2020 | 366 | 0.340 |
Why?
|
| Stem Cells | 1 | 2013 | 383 | 0.340 |
Why?
|
| Thrombocythemia, Essential | 3 | 2021 | 15 | 0.330 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 407 | 0.330 |
Why?
|
| Janus Kinases | 3 | 2020 | 23 | 0.320 |
Why?
|
| Recurrence | 9 | 2021 | 1180 | 0.320 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 27 | 0.310 |
Why?
|
| Pyridines | 3 | 2021 | 311 | 0.310 |
Why?
|
| Prospective Studies | 7 | 2024 | 4468 | 0.300 |
Why?
|
| Chromosome Aberrations | 5 | 2023 | 383 | 0.300 |
Why?
|
| Naphthyridines | 2 | 2021 | 27 | 0.300 |
Why?
|
| Telomerase | 2 | 2021 | 68 | 0.300 |
Why?
|
| Pyridones | 3 | 2022 | 58 | 0.270 |
Why?
|
| Polycythemia Vera | 3 | 2013 | 23 | 0.270 |
Why?
|
| Piperazines | 5 | 2014 | 288 | 0.270 |
Why?
|
| DNA Repair | 1 | 2008 | 366 | 0.260 |
Why?
|
| Oligonucleotides | 3 | 2021 | 91 | 0.250 |
Why?
|
| Risk Factors | 6 | 2023 | 5704 | 0.250 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2015 | 164 | 0.250 |
Why?
|
| Young Adult | 17 | 2025 | 6624 | 0.250 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 186 | 0.250 |
Why?
|
| Leukemia, Myeloid | 3 | 2014 | 251 | 0.240 |
Why?
|
| Anemia | 2 | 2024 | 133 | 0.240 |
Why?
|
| Maximum Tolerated Dose | 5 | 2016 | 268 | 0.240 |
Why?
|
| Eligibility Determination | 1 | 2025 | 36 | 0.240 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 207 | 0.230 |
Why?
|
| Administration, Oral | 5 | 2025 | 673 | 0.230 |
Why?
|
| Cladribine | 1 | 2004 | 35 | 0.230 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 128 | 0.230 |
Why?
|
| Epigenesis, Genetic | 4 | 2014 | 538 | 0.230 |
Why?
|
| Survival Analysis | 11 | 2020 | 1511 | 0.220 |
Why?
|
| Imatinib Mesylate | 5 | 2014 | 127 | 0.220 |
Why?
|
| CD47 Antigen | 1 | 2024 | 22 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1398 | 0.220 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.220 |
Why?
|
| Haplotypes | 3 | 2016 | 639 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 1939 | 0.210 |
Why?
|
| Deoxycytidine | 1 | 2004 | 212 | 0.210 |
Why?
|
| Patient Selection | 2 | 2025 | 689 | 0.210 |
Why?
|
| Hematology | 1 | 2023 | 30 | 0.210 |
Why?
|
| Cytogenetic Analysis | 3 | 2011 | 71 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 977 | 0.200 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2022 | 12 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2014 | 132 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 611 | 0.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 56 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 215 | 0.200 |
Why?
|
| Adenine Nucleotides | 2 | 2013 | 63 | 0.200 |
Why?
|
| Arabinonucleosides | 2 | 2013 | 39 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2013 | 79 | 0.190 |
Why?
|
| Antibodies, Neoplasm | 4 | 2010 | 85 | 0.190 |
Why?
|
| Pneumonia | 1 | 2024 | 189 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1576 | 0.190 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 66 | 0.190 |
Why?
|
| Antigens, CD34 | 5 | 2017 | 161 | 0.180 |
Why?
|
| Glycine | 1 | 2021 | 95 | 0.180 |
Why?
|
| Clonal Evolution | 1 | 2020 | 16 | 0.180 |
Why?
|
| Biomedical Research | 2 | 2021 | 404 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 866 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 622 | 0.170 |
Why?
|
| DNA Methylation | 4 | 2020 | 677 | 0.160 |
Why?
|
| Etoposide | 1 | 2020 | 206 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 624 | 0.160 |
Why?
|
| Allografts | 2 | 2017 | 197 | 0.160 |
Why?
|
| Unrelated Donors | 2 | 2017 | 46 | 0.160 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Fetal Blood | 2 | 2017 | 93 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 39 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 131 | 0.150 |
Why?
|
| Philadelphia Chromosome | 1 | 2018 | 44 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2015 | 725 | 0.140 |
Why?
|
| Animals | 9 | 2023 | 28003 | 0.140 |
Why?
|
| Consensus | 3 | 2024 | 376 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2019 | 406 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 364 | 0.140 |
Why?
|
| Neutropenia | 4 | 2022 | 217 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 295 | 0.130 |
Why?
|
| Biomarkers | 2 | 2020 | 1850 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 310 | 0.130 |
Why?
|
| Pyrimidinones | 2 | 2019 | 39 | 0.130 |
Why?
|
| Quality of Life | 4 | 2024 | 1744 | 0.130 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.130 |
Why?
|
| Maleimides | 1 | 2016 | 26 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 1399 | 0.130 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 31 | 0.120 |
Why?
|
| Melphalan | 3 | 2011 | 100 | 0.120 |
Why?
|
| Nitriles | 4 | 2020 | 158 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2016 | 72 | 0.120 |
Why?
|
| Niacinamide | 1 | 2015 | 101 | 0.120 |
Why?
|
| Karyotype | 1 | 2015 | 34 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2007 | 234 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 22 | 0.120 |
Why?
|
| Vidarabine | 3 | 2010 | 144 | 0.120 |
Why?
|
| Thiazoles | 1 | 2015 | 128 | 0.120 |
Why?
|
| Quinolones | 2 | 2005 | 57 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 79 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2016 | 227 | 0.110 |
Why?
|
| Graft Survival | 3 | 2016 | 935 | 0.110 |
Why?
|
| Molecular Biology | 1 | 2015 | 90 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2014 | 26 | 0.110 |
Why?
|
| Drug Monitoring | 2 | 2020 | 116 | 0.110 |
Why?
|
| Acute Disease | 5 | 2022 | 856 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2007 | 963 | 0.110 |
Why?
|
| Indoles | 1 | 2015 | 306 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2023 | 3508 | 0.110 |
Why?
|
| Adolescent | 8 | 2024 | 9504 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 2035 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2013 | 148 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 868 | 0.100 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2012 | 3 | 0.100 |
Why?
|
| Phthalazines | 1 | 2013 | 47 | 0.100 |
Why?
|
| CD40 Antigens | 1 | 2012 | 44 | 0.100 |
Why?
|
| Europe | 2 | 2024 | 328 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 38 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 731 | 0.100 |
Why?
|
| Alemtuzumab | 5 | 2011 | 90 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 172 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2025 | 9703 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 2669 | 0.100 |
Why?
|
| Disease-Free Survival | 5 | 2015 | 1181 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 336 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 173 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 245 | 0.090 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 3 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2022 | 206 | 0.090 |
Why?
|
| Thionucleotides | 2 | 2008 | 55 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 36 | 0.090 |
Why?
|
| Comorbidity | 4 | 2018 | 987 | 0.090 |
Why?
|
| Karyotyping | 1 | 2011 | 252 | 0.090 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 73 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 1016 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 98 | 0.090 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2008 | 111 | 0.090 |
Why?
|
| Dioxygenases | 1 | 2011 | 79 | 0.090 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.090 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2010 | 30 | 0.090 |
Why?
|
| Busulfan | 1 | 2010 | 41 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 1312 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 429 | 0.080 |
Why?
|
| Mice | 5 | 2023 | 12110 | 0.080 |
Why?
|
| Terminal Care | 1 | 2011 | 138 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 163 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2016 | 2978 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2016 | 1110 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 106 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 531 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 680 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2023 | 403 | 0.080 |
Why?
|
| United States | 5 | 2024 | 7348 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 136 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2012 | 531 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 340 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1733 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.070 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1310 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2024 | 2369 | 0.070 |
Why?
|
| Chimerism | 2 | 2020 | 37 | 0.070 |
Why?
|
| Blood Component Removal | 1 | 2008 | 26 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2008 | 125 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 50 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 86 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 61 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 547 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 205 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 167 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 324 | 0.070 |
Why?
|
| Mycoses | 1 | 2007 | 46 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 272 | 0.070 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 28 | 0.070 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 138 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 41 | 0.070 |
Why?
|
| Age Factors | 4 | 2013 | 1905 | 0.070 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 78 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1163 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 209 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2008 | 800 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2020 | 206 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2008 | 340 | 0.060 |
Why?
|
| Survival Rate | 4 | 2014 | 1927 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2007 | 224 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2005 | 91 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1247 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 85 | 0.060 |
Why?
|
| Thalidomide | 2 | 2017 | 56 | 0.060 |
Why?
|
| Androgens | 1 | 2005 | 176 | 0.060 |
Why?
|
| Propensity Score | 1 | 2025 | 165 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2021 | 601 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 307 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2024 | 57 | 0.050 |
Why?
|
| Piperidines | 1 | 2005 | 164 | 0.050 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.050 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2024 | 190 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 36 | 0.050 |
Why?
|
| Milk | 1 | 2023 | 55 | 0.050 |
Why?
|
| Transplantation, Autologous | 2 | 2019 | 355 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2024 | 168 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 249 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2023 | 56 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 43 | 0.050 |
Why?
|
| Fatigue | 1 | 2004 | 177 | 0.050 |
Why?
|
| Cyclopentanes | 1 | 2023 | 27 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 109 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 380 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 296 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 280 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 58 | 0.050 |
Why?
|
| Drug Approval | 2 | 2015 | 67 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 105 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2023 | 153 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 114 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 2498 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2022 | 265 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1294 | 0.050 |
Why?
|
| Ketoglutaric Acids | 1 | 2021 | 13 | 0.050 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2021 | 7 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 416 | 0.050 |
Why?
|
| NADP | 1 | 2021 | 49 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 80 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 214 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2016 | 445 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 146 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 153 | 0.040 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 900 | 0.040 |
Why?
|
| Capsules | 1 | 2020 | 38 | 0.040 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2020 | 14 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2020 | 78 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 48 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 312 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 51 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 661 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 503 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Lysine | 1 | 2021 | 181 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 337 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 390 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 59 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 68 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 153 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 383 | 0.040 |
Why?
|
| Tablets | 1 | 2020 | 126 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 469 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 2447 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2021 | 1142 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 245 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 145 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 98 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 5430 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 99 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 263 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 1513 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 270 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.030 |
Why?
|
| Apoptosis | 1 | 2023 | 1743 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1763 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 734 | 0.030 |
Why?
|
| Incidence | 2 | 2011 | 1661 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2007 | 2458 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 107 | 0.030 |
Why?
|
| Pain, Procedural | 1 | 2016 | 3 | 0.030 |
Why?
|
| Ranitidine | 1 | 2016 | 8 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.030 |
Why?
|
| Anti-Ulcer Agents | 1 | 2016 | 22 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 375 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 989 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2016 | 76 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 225 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 95 | 0.030 |
Why?
|
| Financing, Government | 1 | 2015 | 24 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 29 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 207 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 390 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 321 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 812 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 264 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 71 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2015 | 87 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 323 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 137 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 266 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 149 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 1052 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 561 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 92 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 871 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 165 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 262 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 64 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 31 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1277 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 66 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 100 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 1141 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 85 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2013 | 120 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 38 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 172 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.020 |
Why?
|
| Hospice Care | 1 | 2011 | 42 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2012 | 214 | 0.020 |
Why?
|
| Child | 2 | 2014 | 7334 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1756 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 269 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2011 | 82 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 197 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 172 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 299 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 118 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2011 | 85 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 304 | 0.020 |
Why?
|
| Research | 1 | 2011 | 254 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1228 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 280 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 419 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 159 | 0.020 |
Why?
|
| Family | 1 | 2012 | 324 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2011 | 373 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 485 | 0.020 |
Why?
|
| Health Policy | 1 | 2011 | 190 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 361 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 268 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3775 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 523 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 36 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 97 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 103 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 58 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 451 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1079 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 289 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 3218 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3818 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 125 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 444 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 246 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1025 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2005 | 25 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1477 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 798 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 575 | 0.010 |
Why?
|
| Biological Availability | 1 | 2004 | 91 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 305 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1771 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 795 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1723 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 901 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2394 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2037 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2680 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 3053 | 0.010 |
Why?
|